Ashwani Verma
Stock Analyst at UBS
(3.13)
# 1,226
Out of 4,761 analysts
62
Total ratings
48.89%
Success rate
1.67%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $30 → $27 | $16.74 | +61.29% | 8 | Jan 30, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $162 → $176 | $120.69 | +45.83% | 6 | Jan 30, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $30 → $34 | $36.85 | -7.73% | 2 | Jan 28, 2025 | |
| AVDL Avadel Pharmaceuticals | Maintains: Buy | $22 → $14 | $8.41 | +66.47% | 2 | Jan 13, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $415 → $475 | $361.10 | +31.54% | 4 | Jan 8, 2025 | |
| ACLX Arcellx | Maintains: Buy | $106 → $114 | $63.75 | +78.82% | 2 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $56 | $34.56 | +62.04% | 1 | Sep 10, 2024 | |
| CHRS Coherus BioSciences | Downgrades: Neutral | $4 → $1.5 | $1.07 | +40.19% | 4 | Aug 16, 2024 | |
| BHVN Biohaven | Maintains: Buy | $55 → $54 | $36.91 | +46.30% | 3 | Aug 13, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Neutral | $83 → $79 | $128.60 | -38.57% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $23 | $19.95 | +15.29% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $107 → $105 | $137.75 | -23.77% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $117 → $113 | $136.01 | -16.92% | 5 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $33.42 | -16.22% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $76 → $81 | $39.70 | +104.03% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $25 | $35.32 | -29.22% | 2 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $61 → $92 | $50.26 | +83.05% | 4 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $82.64 | -91.53% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $11.25 | +6.67% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.66 | +803.61% | 1 | Oct 11, 2022 |
Teva Pharmaceutical Industries
Jan 30, 2025
Maintains: Buy
Price Target: $30 → $27
Current: $16.74
Upside: +61.29%
Neurocrine Biosciences
Jan 30, 2025
Maintains: Buy
Price Target: $162 → $176
Current: $120.69
Upside: +45.83%
Exelixis
Jan 28, 2025
Maintains: Neutral
Price Target: $30 → $34
Current: $36.85
Upside: -7.73%
Avadel Pharmaceuticals
Jan 13, 2025
Maintains: Buy
Price Target: $22 → $14
Current: $8.41
Upside: +66.47%
United Therapeutics
Jan 8, 2025
Maintains: Buy
Price Target: $415 → $475
Current: $361.10
Upside: +31.54%
Arcellx
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $63.75
Upside: +78.82%
Harmony Biosciences Holdings
Sep 10, 2024
Initiates: Buy
Price Target: $56
Current: $34.56
Upside: +62.04%
Coherus BioSciences
Aug 16, 2024
Downgrades: Neutral
Price Target: $4 → $1.5
Current: $1.07
Upside: +40.19%
Biohaven
Aug 13, 2024
Maintains: Buy
Price Target: $55 → $54
Current: $36.91
Upside: +46.30%
Intra-Cellular Therapies
Aug 8, 2024
Maintains: Neutral
Price Target: $83 → $79
Current: $128.60
Upside: -38.57%
Aug 8, 2024
Maintains: Buy
Price Target: $25 → $23
Current: $19.95
Upside: +15.29%
Aug 6, 2024
Maintains: Buy
Price Target: $107 → $105
Current: $137.75
Upside: -23.77%
Jul 2, 2024
Maintains: Neutral
Price Target: $117 → $113
Current: $136.01
Upside: -16.92%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $33.42
Upside: -16.22%
Mar 18, 2024
Maintains: Buy
Price Target: $76 → $81
Current: $39.70
Upside: +104.03%
Feb 20, 2024
Downgrades: Sell
Price Target: $25
Current: $35.32
Upside: -29.22%
Jan 24, 2024
Downgrades: Neutral
Price Target: $61 → $92
Current: $50.26
Upside: +83.05%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $82.64
Upside: -91.53%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $11.25
Upside: +6.67%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $1.66
Upside: +803.61%